[18F]FDG PET/CT features for the molecular characterization of primary breast tumors
- 900 Downloads
The aim of this study was to evaluate the role of imaging features derived from [18F]FDG-PET/CT to provide in vivo characterization of breast cancer (BC).
Images from 43 patients with a first diagnosis of BC were reviewed. Images were acquired before any treatment. Histological data were derived from pretreatment biopsy or surgical histological specimen; these included tumor type, grade, ER and PgR receptor status, lymphovascular invasion, Ki67 index, HER2 status, and molecular subtype. Standard parameters (SUVmean, TLG, MTV) and advanced imaging features (histogram-based and shape and size features) were evaluated. Univariate analysis, hierarchical clustering analysis, and exact Fisher’s test were used for statistical analysis of data. Imaging-derived metrics were reduced evaluating the mutual correlation within group of features as well as the mutual correlation between groups of features to form a signature.
A significant correlation was found between some advanced imaging features and the histological type. Different molecular subtypes were characterized by different values of two histogram-based features (median and energy). A significant association was observed between the imaging signature and luminal A and luminal B HER2 negative molecular subtype and also when considering luminal A, luminal B HER2-negative and HER2-positive groups. Similar results were found between the signature and all five molecular subtypes and also when considering the histological types of BC.
Our results suggest a complementary role of standard PET imaging parameters and advanced imaging features for the in vivo biological characterization of BC lesions.
KeywordsBreast cancer [18F]FDG-pet/Ct Radiomics
Compliance with ethical standards
This study was not funded.
Conflict of interest
All authors declare that they have no conflicts of interest.
This retrospective study was approved by the local Ethics Committee.
Informed consent for this retrospective study was obtained from all individual participants included in the study, as part of the consent signed when admitted in the hospital or when submitted to diagnostic procedures.
- 1.Breast cancer. In EUCAN facktsheets. International Agency for Research on Cancer. http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=46&Gender=2. Accessed 15 Jan 2017.
- 6.Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen international breast cancer conference 2015 in Vienna: dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience. 2015;9:518.PubMedPubMedCentralGoogle Scholar
- 12.Kajáry K, Tőkés T, Dank M, et al. Correlation of the value of 118F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer. Nucl Med Commun. 2015;36:28–37.CrossRefPubMedGoogle Scholar
- 22.Agner SC, Rosen MA, Englander S, et al. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study. Radiology. 2014;272:91–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Grimm LJ, Zhang J, Mazurowski MA. Computational approach to radiogenomics of breast cancer: luminal a and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. J Magn Reson Imaging. 2015;42:902–7.CrossRefPubMedGoogle Scholar
- 26.Groheux D, Majdoub M, Tixier F, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015;42:1682–91.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Gallivanone F, Interlenghi M, D’Ambrosio D, et al. An anthropomorphic phantom for advanced image processing of realistic 18F–FDG PET-CT oncological studies. IEEE Nuclear Science Symposium and Medical Imaging Conference Record (NSS/MIC) M04D-20. 2016.Google Scholar